Lv4
460 积分 2023-02-13 加入
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation
15小时前
待确认
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
8天前
已完结
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
17天前
已完结
Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians
17天前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
17天前
已完结
Interleukin-2 Activity in Patients With Extensive Small-Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B
29天前
已完结
CAR-T cell persistence in the treatment of leukemia and lymphoma
1个月前
已完结
Clinical lessons learned from the first leg of the CAR T cell journey
1个月前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
1个月前
已完结
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
1个月前
已完结
皖公网安备34019202002308
